Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase Ⅲ Study of IV Ascorbic Acid in Combination With FOLFOX+/- Bevacizumab vs Treatment With FOLFOX+/- Bevacizumab Alone as First-line Therapy for Advanced Colorectal Cancer

NCT02969681 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT02969681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02969681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase Ⅲ Study of IV Ascorbic Acid in Combination With FOLFOX+/- Bevacizumab vs Treatment With FOLFOX+/- Bevacizumab Alone as First-line Therapy for Advanced Colorectal Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2017
Completion date
December 30, 2020
Enrollment
442 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms